Aviva’s Anika Therapeutics ANIK Stock Holding History

Aviva’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-32,335	Closed	-$1.68M	–	937
2019 Q4	$1.68M	Buy	+32,335	New	+$1.88M	0.01%	844

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aviva's ANIK Position: Q1 2020 in Review

Aviva sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 32,335 shares — an estimated $1.68M sold.

Aviva first reported a position in ANIK in Q4 2019 and held it in 1 quarter. The position peaked at $1.68M in Q4 2019. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

Aviva reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
Aviva sold 32,335 Anika Therapeutics shares in Q1 2020, an estimated $1.68M.
Aviva first reported a position in Anika Therapeutics in Q4 2019 and held it in 1 quarter.
Aviva's Anika Therapeutics position peaked at $1.68M in Q4 2019.
163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Aviva's 13F filing for Q1 2020, filed 14 May 2020.